Document is current

Article History

Received: 21 October 2025

Accepted: 12 February 2026

First Online: 17 April 2026

Declarations

:

: M.B. serves as the Editor-in-Chief of Annals of Hematology. F.E. has consultancy or advisory role for AbbVie, Incyte, Novartis, FibroGen, GlaxoSmithKline (GSK), and Jazz Pharmaceuticals, and has received research grant (institution) from Daiichi Sankyo and Otsuka, all outside the submitted work. A.V. reports grants or contracts from Jazz Pharmaceuticals, AstraZeneca, and AbbVie. A.V. has received consulting fees from Jazz Pharmaceuticals, AbbVie, Servier, Istituto Gentili, Bristol Myers Squibb, Pfizer, Astellas, Otsuka, Janssen, and Daiichi Sankyo. A.V. has also received honoraria from Servier, Jazz Pharmaceuticals, AbbVie, Otsuka, Pfizer, Astellas, Astex, and Janssen, and support for attending meetings and/or travel from Servier, Janssen, AbbVie, Daiichi Sankyo, and Pfizer, all outside the submitted work. F.E., M.L., and A.V. are authors of some of the studies included in this review. The authors declare that they have no other relevant financial or non-financial interests related to the content of this article.